Showing 8461-8470 of 8647 results for "".
- First Series C-Round Closing for Medical Device Company Implandata Ophthalmic Productshttps://modernod.com/news/first-series-c-round-closing-for-medical-device-company-implandata-ophthalmic-products/2480150/Ophthalmic medical device company Implandata Ophthalmic Products announced that the company accomplished a first closing of its Series C funding round. The company was able to raise a “mid-single digit million Euro” amount from a strategic and several institutional and private investo
- President Trump Outlines Plan to Lower Drug Costshttps://modernod.com/news/president-trump-outlines-plan-to-lower-drug-costs/2480151/President Donald Trump on Friday unveiled plans to increase competition in the prescription medicine market and lower patients’ out-of-pocket costs in an effort to tackle high drug prices in the US. Under the plan, dubbed American Patients First, rules preventing government programmes from
- Genome Surgery for Eye Disease Moves Closer to Realityhttps://modernod.com/news/genome-surgery-for-eye-disease-moves-closer-to-reality/2480154/Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. This is the first time researchers have successfully app
- Siemens Healthineers and Hill-Rom to Provide Comprehensive Diabetes Care for Primary Care Facilitieshttps://modernod.com/news/siemens-healthineers-and-hill-rom-to-provide-comprehensive-diabetes-care-for-primary-care-facilities/2480156/Siemens Healthineers and Hill-Rom signed a co-marketing agreement to provide a suite of point-of-care diagnostic instruments that, for the first time, enable primary healthcare providers in the United States to bridge gaps in diabetes care and satisfy value-based quality measures in a single offi
- Free Cataract Removal Surgeries for Those in Needhttps://modernod.com/news/free-cataract-removal-surgeries-for-those-in-need/2480160/The Hawaiian Eye Foundation (HEF) performs free sight-restoring cataract surgeries for those that are uninsured and underinsured in Hawaii. With the incredible support of the Atherton Family Foundation, the 2nd Annual
- Bausch + Lomb Initiates Clinical Trial Evaluating New Ophthalmic Viscosurgical Devicehttps://modernod.com/news/bausch-lomb-initiates-clinical-trial-evaluating-new-ophthalmic-viscosurgical-device/2480163/Bausch + Lomb announced that it has initiated a clinical trial evaluating the safety and efficacy of a new ophthalmic viscosurgical device (OVD). Bausch + Lomb aims to file for premarket approval (PMA) with the FDA at the conclusion of the clinical trial, with plans to bring this next-generation
- Valeant Will Become Bausch Health Companieshttps://modernod.com/news/valeant-will-become-bausch-health-companies-inc/2480165/Valeant Pharmaceuticals International announced that the company will change its name to Bausch Health Companies beginning in July 2018. “Becoming Bausch Health Companies is a major step forward in our transformation,” Joseph C. Papa, chairman and CEO, Valeant, said in a compan
- Takeda Reaches Deal to Buy Shire for $62 Billionhttps://modernod.com/news/takeda-reaches-deal-to-buy-shire-for-around-62-billion/2480166/After several failed attempts, Japanese drugmaker Takeda Pharmaceutical managed to reach an agreement to acquire Shire in a $62 billion deal. The offer is approximately 46 percent cash and 54 percent stock, leaving Shire shareholders owning around half of the combined group. Shire investors will
- Takeda Nears Deal to Buy Shire in Its Biggest Purchasehttps://modernod.com/news/takeda-nears-deal-to-buy-shire-in-its-biggest-purchase/2480167/Takeda Pharmaceutical is nearing an agreement to buy rival drugmaker Shire, people familiar with the matter said, according to a report in Bloomberg. The deal, if appr
- US Sales of Eylea in First Quarter Best Estimateshttps://modernod.com/news/us-sales-of-eylea-in-first-quarter-best-estimates/2480174/Regeneron Pharmaceuticals reported Thursday that first-quarter sales of Eylea in the US rose 15 percent year-over-year to $984 million, besting analyst estimates of around $922 million. The company’s overall sales increased 15 percent to $1.5 billion, in line with forecasts, as net income s